Growth Hormone Inhibits the 11β-Hydroxysteroid Dehydrogenase Type 1 Gene Promoter Activity via Insulin-like Growth Factor I in HepG2 Cells

Authors:

Abstract
11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1), which is highly expressed in liver and adipose tissue, acts predominantly as an 11β-reductase in intact cells and in vivo, catalyzing the conversion of cortisone (E) to cortisol (F) [ 1 ]. 11β-HSD1 enzyme has attracted great interest in recent years due to its potential importance in the development of metabolic syndrome. Transgenic mice overexpressing 11β-HSD1 in white adipose tissue develop central obesity, insulin resistance, and dyslipidemia [ 2 ]. In contrast, 11β-HSD1 knockout mice exhibit improved hepatic insulin sensitivity and lipid profiles [ 3 ]. 11β-HSD1 inhibition has exhibited favorable effects on the improvement of metabolic syndrome, which is thought to be a consequence of decreased intrahepatic glucocorticoids (GCs) regeneration by 11β-HSD1 oxoreductase [ 4 ]. Clinical studies have demonstrated that growth hormone (GH) inhibits 11β-HSD1 activity by measuring urine cortisol and cortisone metabolites [ 5 ]. However, there are few in vitro studies on the regulation of 11β-HSD1 gene expression by GH. In the present study, we used human hepatoma cell line HepG2 cells to investigate the effect of GH treatment on the transcriptional modulation of 11β-HSD1 by assaying gene promoter activity.